## Responsible Oversight and Governance of Environmental Sustainability and Political Engagement by Our Board, its Committees, and Our Executives
Our Board, its committees, and our executives oversee our ESG strategy and our political engagement. The Corporate Responsibility and Compliance Committee ("CRCC") of the Board of Directors oversees our environmental sustainability strategy and activities and our government affairs activities, including our political contributions, public policy positions with respect to pending legislative or other initiatives, as well as the processes by which we make charitable contributions (including the activities of The Amgen Foundation and the Amgen Safety Net Foundation[ 1]). The Board's Audit Committee provides oversight of our disclosure processes in support of our ESG reporting, as well as oversight of assurance of key data in our ESG Report, including progress against our environmental targets. The CRCC and Audit Committee are each composed of independent outside directors and provide regular updates to the Board of Directors. Our executive management provides regular updates to the Board and its committees regarding the status and progress of the Company's ESG activities, including environmental sustainability updates.
Our Senior Vice President, Corporate Affairs leads the Company's ESG efforts. Our cross-functional executive-level ESG Council, chaired by the Senior Vice President, Corporate Affairs, sets and reviews the Company's environmental sustainability strategy and programs, provides guidance on program implementation, and oversees the continuing enhancement of our approach to ESG. The Council regularly evaluates current and emerging ESG-related risk topics that are relevant to our business.
Our ESG framework is built on four strategic pillars discussed below. "Healthy planet," a key strategic pillar, focuses on our prioritization of sustainability and aim to minimize our environmental impact. Initiative steering committees ("ISC"s), each aligned with one of the four strategic pillars, support the ESG Council. Each ISC coordinates the implementation of the strategy for its respective pillar and integrates our ESG strategy into the Company with the support of subject-matter-expert working teams. ISC members identify emerging ESG issues that could impact our business, employees, communities or stakeholders and, when appropriate, raise them with the ESG Council for discussion and analysis.
Our Senior Vice President, Global Government Affairs and Policy leads the Global Government Affairs and Policy ("GGA&P") team with the oversight by the CRCC. Our GGA&P team participates responsibly and constructively in the legislative process by educating elected officials and other policymakers in Washington, D.C., and in state capitols around the U.S. about public policies that are consistent with our mission to serve patients. We are committed to complying with all applicable laws, rules, and regulations that govern our political engagements. Lobbying is highly regulated in the U.S. through a variety of state and federal registration and reporting laws. We require that our employees and outside firms comply with the Lobbying Disclosure Act and Honest Leadership and Open Government Act."
"## Lobbying Activity Transparency
We are transparent about our lobbying activities. At the federal level, we file a quarterly report that lists the issues on which we have conducted federal lobbying activities with the Office of the Clerk of the U.S. House of Representatives and the Secretary of the U.S. Senate. These quarterly lobbying activity reports are available in the House or Senate databases. Additionally, we expect any third parties with which we are affiliated and that engage in federal lobbying activities to report these activities. Annually, we post a list of states where we file lobbying reports and, to the extent available, either links to the reports filed with each state or links to state websites where such information can be found. Our most current report of such state lobbying information can be found here.
A table identifying each U.S. trade association that received dues payments of greater than or equal to $50,000 from us and the portion of these payments identified by the trade association as being used for lobbying expenditures is presented here."
"## Results of Our Annual Review of U.S. Trade and Industry Associations That Conduct Climate Lobbying and Alignment on Climate Lobbying
Environmental sustainability is important to us and, in 2023, we reviewed and analyzed our U.S. trade association memberships with an emphasis on the climate-focused lobbying activities by associations in which Amgen[2] is a member. As noted below, we disclose payments to certain U.S. trade associations, and the specific amounts identified by such trade associations as being used for lobbying expenditures ("Lobbying Support"), here. While Amgen is not providing direct Lobbying Support, we are members of trade associations that align with business interests and policy goals. Our process and methodology included reviewing our memberships and conducting an assessment of climate-related policy and advocacy positions to determine alignment with the Paris Agreement's goal of limiting the global average temperature rise to 1.5 degrees Celsius.
We did not identify any areas of climate-related policy or Paris Agreement misalignment with any such U.S. trade associations. If misalignment with U.S. trade and industry associations in which Amgen is a member is identified in the future, we will consider whether or not to remain a member. We may see a broader value in certain of our memberships, for example sharing of industry best practices. We will continue to closely monitor these associations.
For those U.S. trade and industry associations in which Amgen is a member and conduct climate lobbying, no Amgen executive officer has a leadership role (such as serving on the board or a relevant committee of the board of such entities).